Savara to Present at the Stifel 2019 Healthcare Conference
Savara Inc. (Nasdaq: SVRA), an orphan lung disease company, will be presenting at the Stifel 2019 Healthcare Conference on Tuesday, November 19, 2019 at 3:00 PM ET / 12:00 PM PT at the Lotte New York Palace Hotel. Rob Neville, Savara’s Chief Executive Officer, will represent the Company at the conference.
Interested parties can access a live audio webcast on the Investors page of the Savara website at www.savarapharma.com/investors/events-presentations/. Archived presentations will be available on Savara’s website for 90 days following the events.
About Savara
Savara is an orphan lung disease company. Savara’s pipeline comprises Molgradex, an inhaled granulocyte-macrophage colony-stimulating factor (GM-CSF) in Phase 3 development for autoimmune pulmonary alveolar proteinosis (aPAP), in Phase 2a development for nontuberculous mycobacterial (NTM) lung infection in both non-cystic fibrosis (CF) and CF-affected individuals with chronic NTM lung infection; and AeroVanc, a Phase 3-stage inhaled vancomycin for treatment of persistent methicillin-resistant Staphylococcus aureus (MRSA) lung infection in CF. Savara’s strategy involves expanding its pipeline of potentially best-in-class products through indication expansion, strategic development partnerships and product acquisitions, with the goal of becoming a leading company in its field. Savara’s management team has significant experience in orphan drug development and pulmonary medicine, identifying unmet needs, developing and acquiring new product candidates, and effectively advancing them to approvals and commercialization. More information can be found at www.savarapharma.com. (Twitter: @SavaraPharma, LinkedIn: www.linkedin.com/company/savara-pharmaceuticals/)
View source version on businesswire.com: https://www.businesswire.com/news/home/20191112005108/en/
Savara Inc. Aktie
Derzeit ist die Community gegenüber der Savara Inc. Aktie mit 0 Sell-Einschätzungen und 1 Buy-Einschätzungen noch unentschlossen.
Eine deutliche Steigerung um mehr als 20% ist für Savara Inc. mit einem Kursziel von 5 € gegenüber 3.92 € zu erwarten.